Novo Nordisk is to invest more than $4bn in US manufacturing as it battles to keep up with booming demand for its obesity and diabetes drugs Wegovy and Ozempic medicine Article 543 words 9 votes
Novo Nordisk suggested to senior UK government officials that they could “profile” benefit claimants – those who are most likely to return to the labour market Article 1338 words 17 votes
The ‘breakthrough’ obesity drugs that have stunned researchers fitness medicine Article 2229 words, published Jan 4 2023 17 votes